top of page

Gilead's Dan O'Day on 1Q23 Earnings

BiotechTV's exclusive interview with Gilead Sciences' Chairman & CEO Dan O'Day on the company's Q1 2023 earnings day.



Brad Loncar visited Gilead Science's headquarters in Foster City, California and had the opportunity to interview Chairman and CEO Dan O'Day about Gilead’s business.


Discussed:


- Gilead’s transformation into oncology and other areas.

- The business model of cell therapy.

- The competitive landscape for the ADC medicine Trodelvy.

- Other oncology targets like CD47 and TIGIT.

- Long-acting medicines for HIV.

- What it was like to develop remdesivir during the pandemic.

Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page